8-K: Aerovate Therapeutics' Phase 2b Trial for Pulmonary Hypertension Drug Fails to Meet Primary Endpoint

Aerovate Therapeutics' Phase 2b trial of AV-101 for pulmonary arterial hypertension did not meet its primary endpoint, leading to the halt of the Phase 3 trial.

Summary

• Aerovate Therapeutics announced topline results from the Phase 2b portion of their IMPAHCT trial for AV-101, a drug for pulmonary arterial hypertension.
• The study evaluated three different doses of AV-101 against a placebo over 24 weeks.
• The primary endpoint was the change in pulmonary vascular resistance (PVR), and the secondary endpoint was the change in six-minute walk distance (6MWD).
• The results showed that AV-101 did not achieve a statistically significant improvement in PVR compared to the placebo for any of the doses tested.
• There were also no meaningful improvements in the 6MWD secondary endpoint.
• Based on these results, Aerovate is halting enrollment and shutting down the Phase 3 portion of the IMPAHCT trial and the long-term extension study.
• As of June 15, 2024, Aerovate has approximately $100 million in cash, cash equivalents, and short-term investments.

Sentiment

Score: 2

Explanation: The document reports a significant failure in a key clinical trial, leading to the halt of a Phase 3 study. This is a major setback for the company and is likely to negatively impact investor sentiment.

Positives

• AV-101 was well tolerated across all dose groups in the Phase 2b trial.
• Aerovate has approximately $100 million in cash, cash equivalents, and short-term investments.

Negatives

• The Phase 2b trial did not meet its primary endpoint of improvement in pulmonary vascular resistance (PVR).
• There were no meaningful improvements in the secondary endpoint of six-minute walk distance (6MWD).
• The Phase 3 portion of the IMPAHCT trial and the long-term extension study are being halted.

Risks

• The failure of the Phase 2b trial raises concerns about the future of AV-101 as a treatment for pulmonary arterial hypertension.
• The halting of the Phase 3 trial will likely impact the company's development timeline and future prospects.
• The company's financial position may be affected by the need to re-evaluate its development strategy.

Future Outlook

Aerovate plans to release full data from the Phase 2b portion of IMPAHCT at a later date, the timing of which is to be determined. The company will engage with the study advisory committee and the PAH community to discuss the data and its implications.

Management Comments

• The results of the Phase 2b portion of IMPAHCT were unexpected and disappointing.
• Our immediate focus is on transparently sharing these findings with investigators, patients and the PAH community.
• We will engage closely with the IMPAHCT study advisory committee and the PAH community to thoroughly discuss these data and their implications.

Industry Context

The failure of the Phase 2b trial is a setback for Aerovate and highlights the challenges in developing effective treatments for pulmonary arterial hypertension. This outcome may impact investor confidence in the company and its approach to drug development.

Comparison to Industry Standards

• The failure to meet the primary endpoint is a significant negative compared to other successful Phase 2b trials in the pulmonary hypertension space.
• Companies such as United Therapeutics and Acceleron Pharma have achieved positive results in their clinical trials for PAH treatments, setting a high bar for efficacy.
• The lack of improvement in 6MWD is also concerning, as this is a commonly used measure of functional capacity in PAH patients and is often a key secondary endpoint in clinical trials.
• The halting of the Phase 3 trial is a major deviation from the typical progression of a drug candidate, indicating a significant setback for Aerovate.

Stakeholder Impact

• Shareholders will likely be negatively impacted by the failure of the Phase 2b trial and the halting of the Phase 3 trial.
• Patients with pulmonary arterial hypertension may be disappointed by the lack of progress in developing new treatment options.
• Employees of Aerovate may face uncertainty regarding the company's future direction.

Next Steps

• Aerovate plans to release full data from the Phase 2b portion of IMPAHCT at a later date.
• The company will engage with the IMPAHCT study advisory committee and the PAH community to discuss the data and its implications.

Key Dates

Keywords

Pulmonary Arterial Hypertension, AV-101, Clinical Trial, Phase 2b, IMPAHCT, Drug Development, PVR, 6MWD, Biopharmaceutical, Inhaled Imatinib